País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
Fludarabine phosphate
Accord Healthcare Limited
L01BB; L01BB05
Fludarabine phosphate
25 milligram(s)/millilitre
Concentrate for solution for infusion
Product subject to prescription which may not be renewed (A)
Purine analogues; fludarabine
Not marketed
2014-09-19
PACKAGE LEAFLET: INFORMATION FOR THE USER FLUDARABINE PHOSPHATE 25 MG/ML CONCENTRATE FOR SOLUTION FOR INJECTION OR INFUSION Fludarabine phosphate The name of your medicine is Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion. In the rest of this leaflet your medicine is called Fludarabine phosphate Injection. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, or pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours • If you get any side effects, talk to your doctor, or pharma- cist or nurse. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET 1. What Fludarabine phosphate Injection is and what it is used for 2. What you need to know before you use Fludarabine phosphate Injection 3. How to use Fludarabine phosphate Injection 4. Possible side effects 5. How to store Fludarabine phosphate Injection 6. Contents of the pack and other information 1. WHAT FLUDARABINE PHOSPHATE INJECTION IS AND WHAT IT IS USED FOR Fludarabine phosphate Injection contains the active substance fludarabine phosphate which stops the growth of new cancer cells. All cells of the body produce new cells like themselves by dividing. Fludarabine phosphate Injection is taken up by the cancer cells and stops them dividing. In cancers of the white blood cells (such as chronic lymphocytic leukaemia), the body produces many abnormal white blood cells _(lymphocytes) _and lymph nodes start to grow in various parts of the body. The abnormal white blood cells cannot carry out the normal disease fighting functions and may push aside healthy blood cells. This can result in infections, a decrease in number of red blood cells _(anaemia)_, bruising, severe bleeding or even organ Leer el documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fludarabine Phosphate 25mg/ml Concentrate for Solution for Injection or Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 25 mg fludarabine phosphate. 2 ml of solution contains 50 mg fludarabine phosphate. Excipient with known effect: Each mL contains <1 mmol sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for injection or infusion. Clear, colourless or slightly brownish-yellow solution, essentially free from particles. pH: 6.0 – 7.1 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of B-cell chronic lymphocytic leukaemia (CLL) in adult patients with sufficient bone marrow reserves. First line treatment with Fludarabine should only be initiated in adult patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 25 mg fludarabine phosphate/m 2 body surface area given daily for 5 consecutive days every 28 days by intravenous route (See also section 6.6). The required dose (calculated on the basis of the patient's body surface area) of the reconstituted solution is drawn up into a syringe. For intravenous bolus injection this dose is further diluted in 10 ml sodium chloride 9 mg/ml (0.9%). Alternatively, for infusion, the required dose drawn up in a syringe may be diluted in 100 ml sodium chloride 9 mg/ml (0.9%) and infused over approximately 30 minutes. The duration of treatment depends on the treatment success and the tolerability of the drug. In CLL patients, Fludarabine should be administered up to the achievement of best response (complete or partial remission, usually 6 cycles) and then the drug should be discontinued. _Special populations_ Patients with renal impairment Doses should be adjusted for patients with reduced kidney function. If creatinine cleara Leer el documento completo